<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the ciclosporin administered orally:

reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analogue is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="5856">
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia: decrease of increase of the need for glitazone, due to decrease or increase of the secretion of endogenour glucogon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce self-monitoring of blood glucose and adjust the dosage of glitazone if needed during the treatment with the somatastin analog. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for repaglinde due to decrease or increase of the secretion of endogenous glucagon .</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose, and adjust the dosage of the sulfonamide if needed during the treatment with the somatostatin analog. </COMMENT>
</INTERACTION>
</INTERACTIONS>
